T1	Participants 127 183	patients with mixed dyslipidaemia and metabolic syndrome
T2	Participants 380 405	metabolic syndrome (MetS)
T3	Participants 585 627	patients with mixed dyslipidaemia and MetS
T4	Participants 662 928	patients with low-density lipoprotein cholesterol (LDL-C) > 160 and TG > 200 mg/dl to rosuvastatin monotherapy 40 mg/day (R group, n = 30) or rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day (RF group, n = 30) or ω-3 fatty acids 2 g/day (Rω group, n = 30)
T5	Participants 952 1045	only patients with MetS were included (24, 23 and 24 in the R, RF and Rω groups respectively)
